| |
|
|
| Company Profile | |
| |
|
Research Development |
|
|
| Pipeline | |
| |
| Management Team | |
| |
| Board of Directors | |
| |
| Scientific Advisory Board | |
| |
| Contact Us | |
|
||||
|
|
Home / Company Information / Company Profile / | ||
|
||||
|
Research |
 |
||
|
Genelabs has a long-standing research strategy of targeting infectious diseases with significant unmet medical needs and strong commercial potential. Our drug discovery research efforts are currently focused on the discovery of novel, small-molecules with potent activity against the hepatitis C virus Genelabs’ expertise with antiviral research has allowed us to quickly participate in the race to discover new treatments for chronic HCV infection, which is a serious worldwide medical problem with limited treatment options. According to publicly available estimates from Decision Resources, Inc., the global market for HCV exceeded $3 billion in 2003 and is projected to grow to over $10 billion by 2010. Our discovery efforts are being aggressively directed against critical HCV gene replication targets, with an aim to discover novel, best-in-class HCV inhibitors. © Genelabs Technologies, Inc. All rights reserved. - Terms of Use |